Art Cashin of UBS Financial Services says that if oil falls back below $80 it could put pressure on stocks.
Twitter reported third-quarter earnings on Monday, meeting analysts' estimates for profits and beating on revenue.
Hey, young millionaires: Searching for yield in a volatile market? Here's former NFL star Jack Brewer's advice.
A couple of old-tech stocks offered a good deal of value, portfolio manager Matthew McLennan says.
Aubrey McClendon is back in the hedge fund game, but this time he's taking a far more indirect approach with a pair of fellow Duke grads.
Are Tesla shares about to follow Netflix and Amazon much lower?
Speculation is increasing that the Organization of Petroleum Exporting Countries will reverse course and cut production at its Thanksgiving meeting.
Interest rates will not only remain low, but could soon hit a ceiling in the near term, says Wall Street pro Scott Minerd.
Steve Ballmer stands to gain as much as $1 billion in tax benefits as a result of his $2 billion purchase of the LA Clippers. FT reports.
Most millionaires are concerned about inequality and nearly half support a higher minimum wage and more taxes on the rich, according to a new survey.
Stocks declined Monday as crude dropped below $80 a barrel and Merck & Co. narrowed its 2014 outlook.
Oil dropped below $80 per barrel on Monday morning, and falling prices could impact job growth in the shale industry.
Ferrari is gearing up to start production on its invite-only supercar known as the Ferrari Sergio, and only six people will be able to buy one.
Rates for a 30-year mortgage wavered near historical lows, but credit availability continues to be a problem for potential home buyers.
Discovery Capital has been battered by volatility, according to a report that disclosed losses of more than 20 percent in one of its main funds.
A nurse who had been monitored for Ebola in isolation in New Jersey has been symptom free for 24 hours, and will be released.
Researchers say they have developed a test that can diagnose Ebola within 30 minutes, the BBC reports.
While Fundstrat's Thomas Lee and Deutsche Bank's David Bianco agree on the market's direction, they differed in CNBC interviews over falling oil prices.
The roller coaster ride for Sarepta continues, as it's likely to file for approval of its muscular dystrophy drug in mid-2015.
Merck reported earnings that beat analysts' expectations, but global sales dropped amid patent expirations and a drop in sales of its hep C drugs.